You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNortriptyline
Accession NumberDB00540  (APRD00602)
TypeSmall Molecule
GroupsApproved
DescriptionNortriptyline hydrochloride, the N-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, nortriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, nortriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Nortriptyline exerts less anticholinergic and sedative side effects compared to the tertiary amine TCAs, amitriptyline and clomipramine. Nortriptyline may be used to treat depression, chronic pain (unlabeled use), irritable bowel syndrome (unlabeled use), diabetic neuropathy (unlabeled use), post-traumatic stress disorder (unlabeled use), and for migraine prophylaxis (unlabeled use).
Structure
Thumb
Synonyms
10,11-dihydro-N-Methyl-5H-dibenzo[a,D]cycloheptene-delta(5,gamma)-propylamine
3-(10,11-dihydro-5H-Dibenzo[a,D]cyclohepten-5-ylidene)-N-methyl-1-propanamine
Ateben
Avantyl
Aventyl
Demethylamitriptyline
Desmethylamitriptyline
Noritren
Nortriptyline
Psychostyl
Sensaval
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-nortriptylineCapsule10 mgOralAvanstra Inc2011-11-282014-08-21Canada
Ava-nortriptylineCapsule25 mgOralAvanstra Inc2011-11-282014-08-21Canada
AventylCapsule10 mgOralAa Pharma Inc1965-12-31Not applicableCanada
AventylCapsule25 mgOralAa Pharma Inc1965-12-31Not applicableCanada
Dom-nortriptyline 10mg CapsulesCapsule10 mgOralDominion Pharmacal1995-10-012014-09-08Canada
Dom-nortriptyline 25mg CapsulesCapsule25 mgOralDominion Pharmacal1995-10-012014-09-08Canada
Gen-nortriptyline Capsules 10mgCapsule10 mgOralGenpharm Ulc1997-09-052009-08-05Canada
Gen-nortriptyline Capsules 25mgCapsule25 mgOralGenpharm Ulc1997-09-052009-08-05Canada
NortriptylineCapsule25 mgOralPharmel Inc1998-06-042014-09-08Canada
NortriptylineCapsule10 mgOralPharmel Inc1998-06-042014-09-08Canada
Nortriptyline-10Capsule10 mgOralPro Doc Limitee2008-03-072016-07-18Canada
Nortriptyline-25Capsule25 mgOralPro Doc Limitee2008-03-072016-07-18Canada
NorventylCapsule25 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-02-042014-07-30Canada
NorventylCapsule10 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-02-042014-07-30Canada
Nu-nortriptyline - Cap 10mgCapsule10 mgOralNu Pharm Inc1996-07-232012-09-04Canada
Nu-nortriptyline - Cap 25mgCapsule25 mgOralNu Pharm Inc1996-07-262012-09-04Canada
PamelorCapsule10 mg/1OralMallinckrodt, Inc.2010-08-03Not applicableUs
PamelorCapsule25 mg/1OralMallinckrodt, Inc.2010-08-03Not applicableUs
PamelorCapsule50 mg/1OralMallinckrodt, Inc.2010-08-03Not applicableUs
PamelorCapsule75 mg/1OralMallinckrodt, Inc.2010-08-03Not applicableUs
PMS-nortriptylineCapsule25 mgOralPharmascience Inc1996-08-23Not applicableCanada
PMS-nortriptylineCapsule10 mgOralPharmascience Inc1996-08-23Not applicableCanada
Ratio-nortriptylineCapsule10 mgOralRatiopharm Inc Division Of Teva Canada Limited1999-10-212009-07-17Canada
Ratio-nortriptylineCapsule25 mgOralRatiopharm Inc Division Of Teva Canada Limited1999-10-212009-07-17Canada
Teva-nortriptylineCapsule10 mgOralTeva Canada Limited1998-09-10Not applicableCanada
Teva-nortriptylineCapsule25 mgOralTeva Canada Limited1998-09-10Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-nortriptyline - Cap 10mgCapsule10 mgOralApotex Inc1996-09-26Not applicableCanada
Apo-nortriptyline - Cap 25mgCapsule25 mgOralApotex Inc1996-09-26Not applicableCanada
Nortriptyline HydrochlorideCapsule50 mg/1OralDIRECT RX2014-01-01Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralREMEDYREPACK INC.2011-09-212016-11-10Us
Nortriptyline HydrochlorideCapsule10 mg/1OralPhysicians Total Care, Inc.2009-06-09Not applicableUs
Nortriptyline HydrochlorideCapsule75 mg/1Oralbryant ranch prepack1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralUnit Dose Services1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule75 mg/1OralMayne Pharma Inc.2016-07-18Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralRebel Distributors Corp1992-03-30Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralA S Medication Solutions1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralLake Erie Medical DBA Quality Care Products LLC1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2000-05-08Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralProficient Rx LP1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralA S Medication Solutions2000-05-08Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralREMEDYREPACK INC.2010-08-10Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralKAISER FOUNDATION HOSPITALS2014-06-17Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralAidarex Pharmaceuticals LLC1995-04-06Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralPreferred Pharmaceuticals Inc.2015-08-17Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-08Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralSt Marys Medical Park Pharmacy2014-05-23Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralAmerican Health Packaging1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule75 mg/1OralClinical Solutions Wholesale1995-04-05Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralREMEDYREPACK INC.2016-08-12Not applicableUs
Nortriptyline HydrochlorideCapsule75 mg/1OralWatson Laboratories, Inc.1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralAidarex Pharmaceuticals LLC2000-05-08Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralREMEDYREPACK INC.2010-11-16Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralPhysicians Total Care, Inc.1993-09-10Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1Oralbryant ranch prepack1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralTeva Pharmaceuticals Usa, Inc.1995-04-05Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralMayne Pharma Inc.2016-07-18Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralRebel Distributors Corp1992-03-30Not applicableUs
Nortriptyline HydrochlorideSolution10 mg/5mLOralPharmaceutical Associates, Inc.2000-08-23Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralREMEDYREPACK INC.2011-12-12Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralCardinal Health2011-05-19Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralDispensing Solutions, Inc.1995-04-05Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralUnit Dose Services1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralClinical Solutions Wholesale, Llc2000-05-08Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralWatson Laboratories, Inc.1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralREMEDYREPACK INC.2016-10-18Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2000-05-08Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralProficient Rx LP1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralA S Medication Solutions1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralA S Medication Solutions2000-05-08Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralREMEDYREPACK INC.2016-08-19Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralAidarex Pharmaceuticals LLC1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralPreferred Pharmaceuticals, Inc.2012-03-05Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-05Not applicableUs
Nortriptyline HydrochlorideCapsule75 mg/1OralREMEDYREPACK INC.2014-08-29Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralClinical Solutions Wholesale1995-04-05Not applicableUs
Nortriptyline HydrochlorideCapsule75 mg/1OralTeva Pharmaceuticals Usa, Inc.1995-04-05Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralMayne Pharma Inc.2016-07-18Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralBlenheim Pharmacal, Inc.2013-11-14Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralProficient Rx LP2000-05-08Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralREMEDYREPACK INC.2011-03-30Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralPhysicians Total Care, Inc.2004-02-25Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1Oralbryant ranch prepack1995-04-05Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralRebel Distributors Corp1992-03-30Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralPreferred Pharmaceuticals, Inc.2015-05-07Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralREMEDYREPACK INC.2011-05-13Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralPd Rx Pharmaceuticals, Inc.1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralAphena Pharma Solutions Tennessee, Llc1995-04-06Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralClinical Solutions Wholesale1995-04-05Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralClinical Solutions Wholesale, Llc2000-05-08Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralWatson Laboratories, Inc.1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralDIRECT RX2014-01-01Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralMedsource Pharmaceuticals1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule75 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2000-05-08Not applicableUs
Nortriptyline HydrochlorideCapsule75 mg/1OralProficient Rx LP1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralTeva Pharmaceuticals Usa, Inc.1995-04-05Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralA S Medication Solutions2000-05-08Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralCarilion Materials Management1995-04-06Not applicableUs
Nortriptyline HydrochlorideCapsule75 mg/1OralREMEDYREPACK INC.2016-09-06Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralAidarex Pharmaceuticals LLC1995-04-05Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralPreferred Pharmaceuticals, Inc.2012-03-05Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralUnit Dose Services1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralDIRECT RX2015-01-01Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralREMEDYREPACK INC.2013-03-012016-11-08Us
Nortriptyline HydrochlorideCapsule75 mg/1OralPhysicians Total Care, Inc.2008-11-11Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1Oralbryant ranch prepack2010-11-03Not applicableUs
Nortriptyline HydrochlorideCapsule75 mg/1OralREMEDYREPACK INC.2010-01-28Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralMayne Pharma Inc.2016-07-18Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralSTAT Rx USA LLC1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralProficient Rx LP1995-04-05Not applicableUs
Nortriptyline HydrochlorideCapsule75 mg/1OralRebel Distributors Corp1992-03-30Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralPreferred Pharmaceuticals, Inc.2012-03-05Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-01-27Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralPd Rx Pharmaceuticals, Inc.1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralAmerican Health Packaging1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralClinical Solutions Wholesale1995-04-06Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralClinical Solutions Wholesale, Llc2000-05-08Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralWatson Laboratories, Inc.1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralPd Rx Pharmaceuticals, Inc.2016-07-18Not applicableUs
Nortriptyline HydrochlorideCapsule75 mg/1OralMedsource Pharmaceuticals2000-05-08Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralREMEDYREPACK INC.2014-06-11Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralProficient Rx LP1992-07-01Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralTeva Pharmaceuticals Usa, Inc.1995-04-06Not applicableUs
Nortriptyline HydrochlorideCapsule50 mg/1OralA S Medication Solutions2000-05-08Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2000-05-08Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralDIRECT RX2015-01-01Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralREMEDYREPACK INC.2007-10-09Not applicableUs
Nortriptyline HydrochlorideCapsule10 mg/1OralProficient Rx LP2000-05-08Not applicableUs
Nortriptyline HydrochlorideCapsule75 mg/1OralAidarex Pharmaceuticals LLC1995-04-05Not applicableUs
Nortriptyline HydrochlorideCapsule25 mg/1OralPreferred Pharmaceuticals, Inc.2015-04-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AllegronNot Available
NoritrenNot Available
NorpressNot Available
NortrilenNot Available
SensovalNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Nortriptyline Hydrochloride
894-71-3
Thumb
  • InChI Key: SHAYBENGXDALFF-UHFFFAOYSA-N
  • Monoisotopic Mass: 299.144077416
  • Average Mass: 299.838
DBSALT000641
Categories
UNIIBL03SY4LXB
CAS number72-69-5
WeightAverage: 263.3767
Monoisotopic: 263.167399677
Chemical FormulaC19H21N
InChI KeyPHVGLTMQBUFIQQ-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3
IUPAC Name
methyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine
SMILES
CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
Pharmacology
IndicationFor the treatment of depression, chronic pain, irritable bowel syndrome, sleep disorders, diabetic neuropathy, agitation and insomnia, and migraine prophylaxis.
Structured Indications
PharmacodynamicsSimilar to protriptyline, nortriptyline is a tricyclic antidepressant of the dibenzocycloheptene type and is the active metabolite of amitriptyline.
Mechanism of actionIt is believed that nortriptyline either inhibits the reuptake of the neurotransmitter serotonin at the neuronal membrane or acts at beta-adrenergic receptors. Tricyclic antidepressants do not inhibit monoamine oxidase nor do they affect dopamine reuptake.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent noradrenaline transporterProteinyes
inhibitor
HumanP23975 details
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
5-hydroxytryptamine receptor 1AProteinunknown
antagonist
HumanP08908 details
Histamine H1 receptorProteinno
antagonist
HumanP35367 details
Alpha-1A adrenergic receptorProteinno
antagonist
HumanP35348 details
Alpha-1D adrenergic receptorProteinno
antagonist
HumanP25100 details
Muscarinic acetylcholine receptor M1Proteinno
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinno
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinno
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinno
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinno
antagonist
HumanP08912 details
5-hydroxytryptamine receptor 2CProteinunknown
antagonist
HumanP28335 details
5-hydroxytryptamine receptor 6Proteinunknown
binder
HumanP50406 details
Alpha-1B adrenergic receptorProteinunknown
antagonist
HumanP35368 details
Alpha-2 adrenergic receptorProtein groupunknown
antagonist
Humannot applicabledetails
Beta adrenergic receptorProtein groupunknown
antagonist
Humannot applicabledetails
D(2) dopamine receptorProteinunknown
antagonist
HumanP14416 details
Sigma receptorProtein groupunknown
binder
Humannot applicabledetails
5-hydroxytryptamine receptor 2CProteinunknown
antagonist
RatP08909 details
Related Articles
AbsorptionWell absorbed from the GI tract. Peak plasma concentrations occur 7-8.5 hours following oral administration.
Volume of distributionNot Available
Protein bindingHighly protein-bound in plasma and tissues.
Metabolism

Undergoes hepatic metabolism via the same pathway as other TCAs.

SubstrateEnzymesProduct
Nortriptyline
E-10-HydroxynortriptylineDetails
Nortriptyline
DesmethylnortriptylineDetails
E-10-Hydroxynortriptyline
Not Available
E-10-HydroxydesmethylnortriptylineDetails
Desmethylnortriptyline
E-10-HydroxydesmethylnortriptylineDetails
Route of eliminationApproximately one-third of a single orally administered dose is excreted in urine within 24 hours. Small amounts are excreted in feces via biliary elimination.
Half life16 to 90+ hours
ClearanceNot Available
ToxicitySymptoms of overdose include cardiac dysrhythmias, severe hypotension, shock, congestive heart failure, pulmonary edema, convulsions, and CNS depression, including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic antidepressant toxicity. Side effects include: sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4A AllelePoor drug metabolizer, lower dose requirements, higher risk for adverse side effects18070221
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs1045642 Not AvailableT Allele, homozygousPostural hypotension12082591
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with 1,1,1,2 Tetrafluoroethane.Investigational
1,10-PhenanthrolineThe serum concentration of Nortriptyline can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineNortriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Nortriptyline can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineNortriptyline may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineNortriptyline may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Nortriptyline can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
4-Bromo-2,5-dimethoxyamphetamineNortriptyline may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineNortriptyline may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Nortriptyline.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Nortriptyline.Experimental
AbirateroneThe serum concentration of Nortriptyline can be increased when it is combined with Abiraterone.Approved
AcenocoumarolNortriptyline may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Nortriptyline.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Nortriptyline.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Acetophenazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Nortriptyline.Investigational
AgmatineNortriptyline may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Nortriptyline.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Nortriptyline.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Nortriptyline.Approved, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Nortriptyline can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Nortriptyline can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Nortriptyline.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Nortriptyline.Approved, Illicit, Investigational
AltretamineAltretamine may increase the orthostatic hypotensive activities of Nortriptyline.Approved
AmiodaroneThe metabolism of Nortriptyline can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Nortriptyline.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Nortriptyline.Approved
AmobarbitalThe metabolism of Nortriptyline can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Nortriptyline.Experimental
AmphetamineNortriptyline may increase the stimulatory activities of Amphetamine.Approved, Illicit
AmprenavirThe serum concentration of Nortriptyline can be increased when it is combined with Amprenavir.Approved
AnagrelideNortriptyline may increase the QTc-prolonging activities of Anagrelide.Approved
Antithrombin III humanThe serum concentration of Nortriptyline can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Nortriptyline can be increased when it is combined with Apixaban.Approved
ApomorphineNortriptyline may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineNortriptyline may decrease the antihypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Nortriptyline can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Nortriptyline can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Nortriptyline can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Nortriptyline.Approved, Investigational
ArmodafinilThe metabolism of Nortriptyline can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideNortriptyline may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherNortriptyline may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Nortriptyline.Approved
AsenapineNortriptyline may increase the QTc-prolonging activities of Asenapine.Approved
AsunaprevirThe serum concentration of Nortriptyline can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Nortriptyline can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Nortriptyline can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Nortriptyline.Vet Approved
AzelastineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Azelastine.Approved
AzithromycinNortriptyline may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Nortriptyline.Approved
BambuterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Bambuterol.Approved
BarbexacloneThe metabolism of Nortriptyline can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Nortriptyline can be increased when combined with Barbital.Illicit
BatimastatThe serum concentration of Nortriptyline can be increased when it is combined with Batimastat.Experimental
BedaquilineNortriptyline may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe serum concentration of Nortriptyline can be increased when it is combined with Benazepril.Approved, Investigational
BenmoxinBenmoxin may increase the serotonergic activities of Nortriptyline.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Nortriptyline can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Nortriptyline.Approved
BenzphetamineNortriptyline may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Nortriptyline.Approved
BetaxololThe metabolism of Nortriptyline can be decreased when combined with Betaxolol.Approved
BethanidineNortriptyline may decrease the antihypertensive activities of Bethanidine.Approved
BexaroteneThe serum concentration of Nortriptyline can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Nortriptyline can be increased when it is combined with Bi201335.Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Bifeprunox.Investigational
BivalirudinThe serum concentration of Nortriptyline can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Nortriptyline can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Nortriptyline can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Nortriptyline can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Brexpiprazole.Approved
BrimonidineNortriptyline may decrease the antihypertensive activities of Brimonidine.Approved
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Nortriptyline.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Nortriptyline.Approved, Illicit
BromocriptineNortriptyline may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Nortriptyline.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nortriptyline.Approved, Investigational
BuprenorphineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Nortriptyline can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Nortriptyline.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nortriptyline.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Nortriptyline.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Nortriptyline.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Nortriptyline.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Nortriptyline.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nortriptyline.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nortriptyline.Approved
CaffeineThe metabolism of Nortriptyline can be decreased when combined with Caffeine.Approved
CandoxatrilThe serum concentration of Nortriptyline can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Nortriptyline can be increased when it is combined with Candoxatrilat.Experimental
CapecitabineThe metabolism of Nortriptyline can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Nortriptyline can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Nortriptyline can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Nortriptyline.Illicit, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Nortriptyline.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Nortriptyline.Withdrawn
CelecoxibThe metabolism of Nortriptyline can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Nortriptyline can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Nortriptyline.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Nortriptyline.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Nortriptyline can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Nortriptyline.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Nortriptyline.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Nortriptyline.Approved
ChloroquineNortriptyline may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Chlorphenamine.Approved
ChlorphentermineNortriptyline may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineNortriptyline may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Nortriptyline.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Nortriptyline.Approved
CholecalciferolThe metabolism of Nortriptyline can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
ChymostatinThe serum concentration of Nortriptyline can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Nortriptyline can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Nortriptyline can be increased when it is combined with Cilazapril.Approved
CimetidineThe metabolism of Nortriptyline can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Nortriptyline can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Nortriptyline.Approved, Vet Approved
CiprofloxacinNortriptyline may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolineNortriptyline may increase the vasopressor activities of Cirazoline.Experimental
CisaprideNortriptyline may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Citalopram.Approved
ClarithromycinThe metabolism of Nortriptyline can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Nortriptyline can be decreased when combined with Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clenbuterol.Approved, Vet Approved
ClidiniumThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clidinium.Approved
ClobazamThe metabolism of Nortriptyline can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Nortriptyline.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clonazepam.Approved, Illicit
ClonidineNortriptyline may decrease the antihypertensive activities of Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nortriptyline.Approved, Illicit
ClotrimazoleThe metabolism of Nortriptyline can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineNortriptyline may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Nortriptyline can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Nortriptyline can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Nortriptyline.Approved, Illicit
ConivaptanThe serum concentration of Nortriptyline can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibNortriptyline may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Nortriptyline can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Nortriptyline.Approved
Cyproterone acetateThe serum concentration of Nortriptyline can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Nortriptyline can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Nortriptyline can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Nortriptyline.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Nortriptyline.Investigational
DarifenacinThe metabolism of Nortriptyline can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Nortriptyline can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Nortriptyline can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Nortriptyline can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Nortriptyline can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Nortriptyline.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nortriptyline.Approved
DesipramineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Nortriptyline.Vet Approved
DexamethasoneThe serum concentration of Nortriptyline can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nortriptyline.Approved
DexmedetomidineNortriptyline may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Nortriptyline.Approved
DextroamphetamineNortriptyline may increase the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Nortriptyline.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Nortriptyline.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Nortriptyline.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Nortriptyline.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Nortriptyline.Approved, Illicit, Vet Approved
DicoumarolNortriptyline may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionNortriptyline may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nortriptyline.Approved, Illicit
DihydroergotamineNortriptyline may decrease the antihypertensive activities of Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Nortriptyline.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Nortriptyline.Experimental, Illicit
DiltiazemThe metabolism of Nortriptyline can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Nortriptyline can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Nortriptyline.Approved, Illicit
DipivefrinNortriptyline may decrease the antihypertensive activities of Dipivefrin.Approved
DisopyramideNortriptyline may increase the QTc-prolonging activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Dobutamine.Approved
DofetilideNortriptyline may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronNortriptyline may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneNortriptyline may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Nortriptyline.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Doxepin.Approved
DoxycyclineThe metabolism of Nortriptyline can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Nortriptyline.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved, Illicit
DronedaroneNortriptyline may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Nortriptyline.Experimental, Illicit
DroxidopaNortriptyline may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Nortriptyline.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Nortriptyline.Approved
EcabetThe serum concentration of Nortriptyline can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Nortriptyline.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Nortriptyline.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Nortriptyline can be increased when it is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Nortriptyline can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Nortriptyline can be increased when it is combined with Elafin.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Nortriptyline.Approved, Investigational
EliglustatNortriptyline may increase the QTc-prolonging activities of Eliglustat.Approved
EnalaprilThe serum concentration of Nortriptyline can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Nortriptyline can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Nortriptyline can be increased when it is combined with Enalkiren.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Nortriptyline.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Nortriptyline.Approved, Investigational
EnzalutamideThe serum concentration of Nortriptyline can be decreased when it is combined with Enzalutamide.Approved
EphedraNortriptyline may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineNortriptyline may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ergonovine.Approved
ErgotamineNortriptyline may decrease the antihypertensive activities of Ergotamine.Approved
ErythromycinNortriptyline may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Nortriptyline can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Nortriptyline can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Nortriptyline.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Nortriptyline.Approved
EthanolNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nortriptyline.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ethotoin.Approved
Ethyl biscoumacetateNortriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Nortriptyline.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Nortriptyline.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Nortriptyline.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Nortriptyline.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Nortriptyline.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Nortriptyline.Approved
EtomidateNortriptyline may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Nortriptyline.Illicit, Vet Approved
EtravirineThe serum concentration of Nortriptyline can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Nortriptyline.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nortriptyline.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fexofenadine.Approved
FlecainideNortriptyline may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Flibanserin.Approved
FloxuridineThe metabolism of Nortriptyline can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Nortriptyline can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Nortriptyline.Approved, Illicit
FluindioneNortriptyline may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Nortriptyline.Approved, Illicit
FluorouracilThe metabolism of Nortriptyline can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Nortriptyline.Approved, Vet Approved
FlupentixolNortriptyline may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Nortriptyline.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Nortriptyline.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Nortriptyline.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Nortriptyline can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Nortriptyline.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Nortriptyline can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nortriptyline can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Nortriptyline can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Nortriptyline can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Nortriptyline.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Nortriptyline.Approved, Vet Approved
Fusidic AcidThe serum concentration of Nortriptyline can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nortriptyline.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Nortriptyline is combined with gabapentin enacarbil.Approved
GabexateThe serum concentration of Nortriptyline can be increased when it is combined with Gabexate.Investigational
Gadobenic acidNortriptyline may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Nortriptyline.Approved, Illicit
GeldanamycinThe serum concentration of Nortriptyline can be increased when it is combined with Geldanamycin.Experimental
GemfibrozilThe metabolism of Nortriptyline can be decreased when combined with Gemfibrozil.Approved
GemifloxacinNortriptyline may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Nortriptyline.Approved, Illicit
GM6001The serum concentration of Nortriptyline can be increased when it is combined with GM6001.Experimental
GoserelinNortriptyline may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronNortriptyline may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanabenzNortriptyline may decrease the antihypertensive activities of Guanabenz.Approved
GuanfacineNortriptyline may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Nortriptyline.Approved, Illicit, Withdrawn
HaloperidolNortriptyline may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Nortriptyline.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Nortriptyline.Approved, Illicit
HexobarbitalThe metabolism of Nortriptyline can be increased when combined with Hexobarbital.Approved
HirulogThe serum concentration of Nortriptyline can be increased when it is combined with Hirulog.Experimental
HydracarbazineHydracarbazine may increase the serotonergic activities of Nortriptyline.Approved
HydrocodoneNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Nortriptyline.Approved, Illicit
Hydroxyamphetamine hydrobromideNortriptyline may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
IbutilideNortriptyline may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Nortriptyline can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Nortriptyline can be increased when it is combined with idraparinux.Investigational
IloperidoneNortriptyline may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Nortriptyline can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Nortriptyline can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nortriptyline.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Nortriptyline can be decreased when combined with Indinavir.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Nortriptyline.Approved
IproclozideIproclozide may increase the serotonergic activities of Nortriptyline.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Nortriptyline.Withdrawn
IrbesartanThe metabolism of Nortriptyline can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Nortriptyline can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Nortriptyline.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nortriptyline.Approved, Vet Approved
IsoflurophateThe serum concentration of Nortriptyline can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe metabolism of Nortriptyline can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Isoprenaline.Approved
IsradipineThe metabolism of Nortriptyline can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Nortriptyline can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Nortriptyline can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Nortriptyline can be increased when it is combined with Ixazomib.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Nortriptyline.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Nortriptyline.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Nortriptyline.Approved
KetoconazoleThe metabolism of Nortriptyline can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Lamotrigine.Approved, Investigational
LeflunomideThe metabolism of Nortriptyline can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibNortriptyline may increase the QTc-prolonging activities of Lenvatinib.Approved
LepirudinThe serum concentration of Nortriptyline can be increased when it is combined with Lepirudin.Approved
LeuprolideNortriptyline may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nortriptyline.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levodopa.Approved
LevofloxacinNortriptyline may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Nortriptyline.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Nortriptyline.Approved
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Nortriptyline.Approved
LidocaineThe metabolism of Nortriptyline can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Nortriptyline can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Nortriptyline.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Nortriptyline.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Nortriptyline.Approved
LisdexamfetamineNortriptyline may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Nortriptyline can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Nortriptyline.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Nortriptyline.Illicit
LofexidineNortriptyline may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Nortriptyline can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Nortriptyline.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Nortriptyline.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Lorcaserin.Approved
LosartanThe metabolism of Nortriptyline can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Nortriptyline can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Nortriptyline.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Nortriptyline.Investigational
LuliconazoleThe serum concentration of Nortriptyline can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Nortriptyline can be decreased when it is combined with Lumacaftor.Approved
LumefantrineNortriptyline may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Nortriptyline.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Maprotiline.Approved
MebanazineMebanazine may increase the serotonergic activities of Nortriptyline.Withdrawn
MeclizineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Nortriptyline.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Nortriptyline.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Nortriptyline.Approved
MephedroneNortriptyline may increase the stimulatory activities of Mephedrone.Investigational
MephentermineNortriptyline may increase the vasopressor activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Nortriptyline.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nortriptyline.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Nortriptyline.Approved
MetaraminolNortriptyline may increase the vasopressor activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Nortriptyline.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Nortriptyline.Approved, Illicit
MethamphetamineNortriptyline may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Nortriptyline.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Nortriptyline.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Nortriptyline.Approved, Vet Approved
MethohexitalThe metabolism of Nortriptyline can be increased when combined with Methohexital.Approved
MethotrimeprazineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineNortriptyline may increase the vasopressor activities of Methoxamine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Nortriptyline.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Methsuximide.Approved
Methylene blueNortriptyline may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Nortriptyline.Approved, Investigational
MethylphenobarbitalThe metabolism of Nortriptyline can be increased when combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Nortriptyline.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Nortriptyline.Approved, Investigational
MetyrosineNortriptyline may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Nortriptyline can be decreased when combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Nortriptyline.Approved, Illicit
MidodrineNortriptyline may increase the vasopressor activities of Midodrine.Approved
MifepristoneThe serum concentration of Nortriptyline can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Milnacipran.Approved
MinaprineMinaprine may increase the serotonergic activities of Nortriptyline.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved, Investigational
MirabegronThe metabolism of Nortriptyline can be decreased when combined with Mirabegron.Approved
MirtazapineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Nortriptyline can be decreased when it is combined with Mitotane.Approved
MMDANortriptyline may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic activities of Nortriptyline.Approved
ModafinilThe serum concentration of Nortriptyline can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Nortriptyline can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Nortriptyline.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nortriptyline.Approved, Investigational
MoxifloxacinNortriptyline may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Nortriptyline.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Nortriptyline can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved, Investigational
NafamostatThe serum concentration of Nortriptyline can be increased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Nortriptyline can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Nortriptyline.Approved
NaphazolineNortriptyline may decrease the antihypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Naratriptan.Approved, Investigational
NCX 4016The serum concentration of Nortriptyline can be increased when it is combined with NCX 4016.Investigational
NefazodoneThe metabolism of Nortriptyline can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Nortriptyline can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Nortriptyline can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Nortriptyline can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Nortriptyline.Withdrawn
NicardipineThe metabolism of Nortriptyline can be decreased when combined with Nicardipine.Approved
NicorandilNortriptyline may increase the hypotensive activities of Nicorandil.Approved
NilotinibNortriptyline may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Nortriptyline.Approved
NitroaspirinThe serum concentration of Nortriptyline can be increased when it is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Nortriptyline.Approved, Vet Approved
NorepinephrineNortriptyline may decrease the antihypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Nortriptyline.Approved, Illicit
OctamoxinOctamoxin may increase the serotonergic activities of Nortriptyline.Withdrawn
OfloxacinNortriptyline may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nortriptyline.Approved, Investigational
OlaparibThe metabolism of Nortriptyline can be decreased when combined with Olaparib.Approved
OlodaterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Olopatadine.Approved
OmapatrilatThe serum concentration of Nortriptyline can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Nortriptyline can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronNortriptyline may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Nortriptyline.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Orciprenaline.Approved
OrphenadrineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Nortriptyline.Investigational
OsimertinibThe serum concentration of Nortriptyline can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Nortriptyline can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Nortriptyline.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Nortriptyline.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Nortriptyline.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nortriptyline.Approved, Illicit, Investigational
OxymetazolineNortriptyline may decrease the antihypertensive activities of Oxymetazoline.Approved
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nortriptyline.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Nortriptyline can be increased when it is combined with Palbociclib.Approved
PaliperidoneNortriptyline may decrease the antihypertensive activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Nortriptyline.Approved, Investigational
PanobinostatThe serum concentration of Nortriptyline can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Nortriptyline can be decreased when combined with Pantoprazole.Approved
ParaldehydeNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylinePargyline may increase the serotonergic activities of Nortriptyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Nortriptyline.Approved, Investigational
PazopanibNortriptyline may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Nortriptyline can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineNortriptyline may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nortriptyline.Approved, Vet Approved
PentobarbitalThe metabolism of Nortriptyline can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
PerazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Perazine.Investigational
PerflutrenNortriptyline may increase the QTc-prolonging activities of Perflutren.Approved
PergolideNortriptyline may decrease the antihypertensive activities of Pergolide.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Nortriptyline can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Nortriptyline.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Nortriptyline.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Nortriptyline.Approved
PhenelzinePhenelzine may increase the serotonergic activities of Nortriptyline.Approved
PhenindioneNortriptyline may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Nortriptyline.Withdrawn
PhenobarbitalThe metabolism of Nortriptyline can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Nortriptyline.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Nortriptyline.Withdrawn
PhenprocoumonNortriptyline may increase the anticoagulant activities of Phenprocoumon.Approved
PhentermineNortriptyline may increase the stimulatory activities of Phentermine.Approved, Illicit
PhenylephrineNortriptyline may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineNortriptyline may decrease the antihypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Nortriptyline can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Nortriptyline can be increased when it is combined with Phosphoramidon.Experimental
PimozideNortriptyline may increase the QTc-prolonging activities of Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nortriptyline.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pipotiazine.Approved
PirbuterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Piritramide.Investigational
PirlindolePirlindole may increase the serotonergic activities of Nortriptyline.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Nortriptyline.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Nortriptyline can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleNortriptyline may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Nortriptyline.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Nortriptyline.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Nortriptyline.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Nortriptyline.Approved
PrimaquineNortriptyline may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Nortriptyline can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Nortriptyline can be increased when it is combined with Prinomastat.Investigational
ProcainamideNortriptyline may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Nortriptyline.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Procaterol.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nortriptyline.Approved, Vet Approved
PromazineNortriptyline may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Promethazine.Approved
PropafenoneNortriptyline may increase the QTc-prolonging activities of Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Nortriptyline.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Nortriptyline.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Nortriptyline.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Nortriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Nortriptyline.Investigational
PseudoephedrineNortriptyline may decrease the antihypertensive activities of Pseudoephedrine.Approved
PyrimethamineThe metabolism of Nortriptyline can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Nortriptyline.Approved, Illicit
QuetiapineNortriptyline may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe serum concentration of Nortriptyline can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineNortriptyline may increase the QTc-prolonging activities of Quinidine.Approved
QuinineNortriptyline may increase the QTc-prolonging activities of Quinine.Approved
RacecadotrilThe serum concentration of Nortriptyline can be increased when it is combined with Racecadotril.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Nortriptyline can be increased when it is combined with Ramipril.Approved
RanolazineThe metabolism of Nortriptyline can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Nortriptyline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nortriptyline.Approved
RemikirenThe serum concentration of Nortriptyline can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Nortriptyline.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nortriptyline.Approved
RifabutinThe metabolism of Nortriptyline can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Nortriptyline can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Nortriptyline can be increased when combined with Rifapentine.Approved
RisperidoneNortriptyline may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ritanserin.Investigational
RitobegronNortriptyline may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ritodrine.Approved
RitonavirThe metabolism of Nortriptyline can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Nortriptyline can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Rizatriptan.Approved
RolapitantThe metabolism of Nortriptyline can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Nortriptyline.Vet Approved
RopiniroleNortriptyline may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nortriptyline.Approved
RotigotineNortriptyline may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Nortriptyline.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Nortriptyline.Experimental
SafrazineSafrazine may increase the serotonergic activities of Nortriptyline.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Nortriptyline is combined with Sage 547.Investigational
SalbutamolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Salmeterol.Approved
SaquinavirThe metabolism of Nortriptyline can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Nortriptyline can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Nortriptyline can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Nortriptyline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Nortriptyline.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Nortriptyline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nortriptyline.Approved, Vet Approved
SildenafilThe metabolism of Nortriptyline can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Nortriptyline can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Nortriptyline can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Nortriptyline can be increased when it is combined with Sitagliptin.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
SorafenibThe metabolism of Nortriptyline can be decreased when combined with Sorafenib.Approved, Investigational
SotalolNortriptyline may increase the QTc-prolonging activities of Sotalol.Approved
SpiraprilThe serum concentration of Nortriptyline can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Nortriptyline can be increased when combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Nortriptyline can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nortriptyline.Approved, Investigational
SulfadiazineThe metabolism of Nortriptyline can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Nortriptyline can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Nortriptyline can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Nortriptyline.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Sumatriptan.Approved, Investigational
SuvorexantNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tasimelteon.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Nortriptyline.Approved
TelaprevirThe metabolism of Nortriptyline can be decreased when combined with Telaprevir.Approved
TelavancinNortriptyline may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Nortriptyline can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Nortriptyline.Approved
TemocaprilThe serum concentration of Nortriptyline can be increased when it is combined with Temocapril.Experimental, Investigational
TenofovirThe metabolism of Nortriptyline can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineThe metabolism of Nortriptyline can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Terbutaline.Approved
TeriflunomideThe serum concentration of Nortriptyline can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineNortriptyline may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Nortriptyline.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Nortriptyline.Investigational
ThalidomideNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Nortriptyline can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Nortriptyline can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Nortriptyline can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Nortriptyline.Approved
ThiorphanThe serum concentration of Nortriptyline can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Nortriptyline.Approved
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Nortriptyline.Approved
TiagabineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tiapride.Investigational
TicagrelorThe metabolism of Nortriptyline can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Nortriptyline can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Nortriptyline.Vet Approved
TipranavirThe metabolism of Nortriptyline can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineNortriptyline may decrease the antihypertensive activities of Tizanidine.Approved
TocilizumabThe serum concentration of Nortriptyline can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Nortriptyline can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nortriptyline.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Nortriptyline.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Nortriptyline.Approved
ToremifeneNortriptyline may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolNortriptyline may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Nortriptyline can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Nortriptyline.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Nortriptyline.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Nortriptyline.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nortriptyline.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Nortriptyline.Approved, Vet Approved
TrimethoprimThe metabolism of Nortriptyline can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Nortriptyline.Approved
TropisetronTropisetron may increase the serotonergic activities of Nortriptyline.Investigational
UbenimexThe serum concentration of Nortriptyline can be increased when it is combined with Ubenimex.Experimental
Uc1010The risk or severity of adverse effects can be increased when Nortriptyline is combined with Uc1010.Investigational
UlinastatinThe serum concentration of Nortriptyline can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe serum concentration of Nortriptyline can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Nortriptyline can be decreased when combined with Valsartan.Approved, Investigational
VandetanibNortriptyline may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibThe serum concentration of Nortriptyline can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Nortriptyline.Approved
VerapamilThe metabolism of Nortriptyline can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Vigabatrin.Approved
VilanterolThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Vilazodone.Approved
VildagliptinThe serum concentration of Nortriptyline can be increased when it is combined with Vildagliptin.Approved, Investigational
VoriconazoleThe metabolism of Nortriptyline can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Vortioxetine.Approved
WarfarinNortriptyline may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Nortriptyline can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Nortriptyline.Vet Approved
XylometazolineNortriptyline may decrease the antihypertensive activities of Xylometazoline.Approved
Ym150The serum concentration of Nortriptyline can be increased when it is combined with Ym150.Investigational
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Nortriptyline.Approved, Vet Approved
ZafirlukastThe metabolism of Nortriptyline can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Nortriptyline.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Zimelidine.Withdrawn
ZiprasidoneNortriptyline may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Nortriptyline.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Nortriptyline.Approved, Investigational
ZolpidemNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Nortriptyline.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Nortriptyline.Approved
ZuclopenthixolNortriptyline may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Take with food to reduce irritation.
References
Synthesis Reference

Abraham Nudelman, “ACID ADDITION SALT OF A NORTRIPTYLINE-GABA CONJUGATE AND A PROCESS OF PREPARING SAME.” U.S. Patent US20130184347, issued July 18, 2013.

US20130184347
General References
  1. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D: A randomized trial of nortriptyline for smoking cessation. Arch Intern Med. 1998 Oct 12;158(18):2035-9. [PubMed:9778204 ]
External Links
ATC CodesN06AA10
AHFS Codes
  • 28:16.04.28
PDB EntriesNot Available
FDA labelDownload (420 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9478
Caco-2 permeable+0.774
P-glycoprotein substrateSubstrate0.7863
P-glycoprotein inhibitor IInhibitor0.8876
P-glycoprotein inhibitor IIInhibitor0.5376
Renal organic cation transporterInhibitor0.6903
CYP450 2C9 substrateNon-substrate0.7508
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.5593
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.7665
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5194
Ames testNon AMES toxic0.5315
CarcinogenicityNon-carcinogens0.9182
BiodegradationReady biodegradable0.5
Rat acute toxicity2.7513 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5809
hERG inhibition (predictor II)Inhibitor0.7763
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Taro pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Tyco healthcare group lp
  • Ranbaxy pharmaceuticals inc
  • Pharmaceutical assoc inc
  • Taro pharmaceutical industries ltd
Packagers
Dosage forms
FormRouteStrength
CapsuleOral10 mg
CapsuleOral25 mg
CapsuleOral10 mg/1
SolutionOral10 mg/5mL
CapsuleOral25 mg/1
CapsuleOral50 mg/1
CapsuleOral75 mg/1
Prices
Unit descriptionCostUnit
Pamelor 30 10 mg capsule Bottle750.05USD bottle
Pamelor 30 25 mg capsule Bottle750.05USD bottle
Pamelor 30 50 mg capsule Bottle750.05USD bottle
Pamelor 10 mg/5ml Solution 480ml Bottle325.97USD bottle
Pamelor 10 mg capsule24.04USD capsule
Pamelor 25 mg capsule24.04USD capsule
Pamelor 50 mg capsule24.04USD capsule
Pamelor 75 mg capsule19.34USD capsule
Nortriptyline hcl powder11.09USD g
Nortriptyline hcl 75 mg capsule1.33USD capsule
Nortriptyline hcl 50 mg capsule0.94USD capsule
Nortriptyline hcl 25 mg capsule0.6USD capsule
Aventyl 25 mg Capsule0.48USD capsule
Nortriptyline HCl 10 mg/5ml Solution0.4USD ml
Nortriptyline hcl 10 mg capsule0.28USD capsule
Apo-Nortriptyline 25 mg Capsule0.27USD capsule
Novo-Nortriptyline 25 mg Capsule0.27USD capsule
Nu-Nortriptyline 25 mg Capsule0.27USD capsule
Pms-Nortriptyline 25 mg Capsule0.27USD capsule
Aventyl 10 mg Capsule0.24USD capsule
Apo-Nortriptyline 10 mg Capsule0.13USD capsule
Novo-Nortriptyline 10 mg Capsule0.13USD capsule
Nu-Nortriptyline 10 mg Capsule0.13USD capsule
Pms-Nortriptyline 10 mg Capsule0.13USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point213-215 °CNot Available
logP4.51BRODIN,A (1974)
pKa10.1SANGSTER (2004)
Predicted Properties
PropertyValueSource
Water Solubility0.000874 mg/mLALOGPS
logP4.65ALOGPS
logP4.43ChemAxon
logS-5.5ALOGPS
pKa (Strongest Basic)10.47ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity96.21 m3·mol-1ChemAxon
Polarizability31.87 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.76 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0006-9230000000-15f73e5232a0e230f41bView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene connected by a cycloheptene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassDibenzocycloheptenes
Sub ClassNot Available
Direct ParentDibenzocycloheptenes
Alternative Parents
Substituents
  • Dibenzocycloheptene
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Roubert C, Cox PJ, Bruss M, Hamon M, Bonisch H, Giros B: Determination of residues in the norepinephrine transporter that are critical for tricyclic antidepressant affinity. J Biol Chem. 2001 Mar 16;276(11):8254-60. Epub 2000 Nov 22. [PubMed:11092898 ]
  2. Roubert C, Sagne C, Kapsimali M, Vernier P, Bourrat F, Giros B: A Na(+)/Cl(-)-dependent transporter for catecholamines, identified as a norepinephrine transporter, is expressed in the brain of the teleost fish medaka (Oryzias latipes). Mol Pharmacol. 2001 Sep;60(3):462-73. [PubMed:11502876 ]
  3. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. [PubMed:14744476 ]
  4. Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, Kim DK: Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA. 2006 Oct 4;296(13):1609-18. [PubMed:17018806 ]
  5. Barker EL, Blakely RD: Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol Pharmacol. 1996 Oct;50(4):957-65. [PubMed:8863842 ]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Miller AL, Rogers GR, Kennedy MA: Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol. 2003 Dec;6(4):339-46. [PubMed:14604448 ]
  2. Wisner KL, Hanusa BH, Perel JM, Peindl KS, Piontek CM, Sit DK, Findling RL, Moses-Kolko EL: Postpartum depression: a randomized trial of sertraline versus nortriptyline. J Clin Psychopharmacol. 2006 Aug;26(4):353-60. [PubMed:16855451 ]
  3. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000 Nov;23(5):587-90. [PubMed:11027924 ]
  4. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. [PubMed:14744476 ]
  5. Rausch JL, Moeller FG, Johnson ME: Initial platelet serotonin (5-HT) transport kinetics predict nortriptyline treatment outcome. J Clin Psychopharmacol. 2003 Apr;23(2):138-44. [PubMed:12640215 ]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Sadava D, Wilmington K: Tricyclic antidepressant drugs affect histamine receptors in human leukocytes. Life Sci. 1984 Dec 17;35(25):2545-8. [PubMed:6096660 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J: Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl). 1996 Aug;126(3):234-40. [PubMed:8876023 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Monsma FJ Jr, Shen Y, Ward RP, Hamblin MW, Sibley DR: Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7. [PubMed:7680751 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
  3. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
Components:
NameUniProt IDDetails
Alpha-2A adrenergic receptorP08913 Details
Alpha-2B adrenergic receptorP18089 Details
Alpha-2C adrenergic receptorP18825 Details
References
  1. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
  2. PDSP Ki Database [Link]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Components:
NameUniProt IDDetails
Beta-1 adrenergic receptorP08588 Details
Beta-2 adrenergic receptorP07550 Details
Beta-3 adrenergic receptorP13945 Details
References
  1. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
  2. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Peroutka SJ, Snyder SH: Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet. 1982 Mar 20;1(8273):658-9. [PubMed:6121969 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
  3. PDSP Ki Database [Link]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Receptor for progesterone.
Components:
NameUniProt IDDetails
Membrane-associated progesterone receptor component 1O00264 Details
Sigma non-opioid intracellular receptor 1Q99720 Details
References
  1. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
  2. PDSP Ki Database [Link]
Kind
Protein
Organism
Rat
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
Htr2c
Uniprot ID:
P08909
Molecular Weight:
51916.005 Da
References
  1. Jenck F, Moreau JL, Mutel V, Martin JR, Haefely WE: Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol. 1993 Feb 9;231(2):223-9. [PubMed:8453978 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. doi: 10.1016/j.cbi.2008.02.001. Epub 2008 Feb 14. [PubMed:18359012 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol. 1999 Jun;39(6):567-77. [PubMed:10354960 ]
  5. Olesen OV, Linnet K: Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997 Jun;25(6):740-4. [PubMed:9193876 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. doi: 10.1016/j.cbi.2008.02.001. Epub 2008 Feb 14. [PubMed:18359012 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol. 1999 Jun;39(6):567-77. [PubMed:10354960 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. doi: 10.1016/j.cbi.2008.02.001. Epub 2008 Feb 14. [PubMed:18359012 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Olesen OV, Linnet K: Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997 Jun;25(6):740-4. [PubMed:9193876 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Olesen OV, Linnet K: Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997 Jun;25(6):740-4. [PubMed:9193876 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. doi: 10.1016/j.cbi.2008.02.001. Epub 2008 Feb 14. [PubMed:18359012 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Brinkschulte M, Breyer-Pfaff U: The contribution of alpha 1-acid glycoprotein, lipoproteins, and albumin to the plasma binding of perazine, amitriptyline, and nortriptyline in healthy man. Naunyn Schmiedebergs Arch Pharmacol. 1980 Oct;314(1):61-6. [PubMed:6108517 ]
Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Brinkschulte M, Breyer-Pfaff U: The contribution of alpha 1-acid glycoprotein, lipoproteins, and albumin to the plasma binding of perazine, amitriptyline, and nortriptyline in healthy man. Naunyn Schmiedebergs Arch Pharmacol. 1980 Oct;314(1):61-6. [PubMed:6108517 ]
  2. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11